Completed PHASE1 INTERVENTIONAL 1-arm NCT00338026

A Phase I Study of ECO-4601 in Patients With Advanced Cancer

A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose

Sponsor: Thallion Pharmaceuticals

Conditions Breast Cancer Colorectal Cancer Glioma Lung Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer Tumors

Interventions ECO-4601

Updated 5 times since 2017 Last updated: Jul 10, 2008 Started: Feb 28, 2006 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer and Colorectal Cancer, this trial is completed. The trial is conducted by Thallion Pharmaceuticals and has accumulated 5 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Thallion Pharmaceuticals

Data source: Thallion Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Greenfield Park, Canada
• Montreal, Canada